TrialPath

Find a study

Match me to a study

169 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

150 studies on the map

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) — University of Colorado Anschutz Medical Campus, AuroraTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamRESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus — University of California Irvine, OrangeA Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease — Mayo Clinic, PhoenixA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease — Wallace Rheumatic Center, Beverly HillsA Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) — Nkarta Investigational Site, Little RockA Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE — Research Site, San FranciscoTreatment of Moderate to Severe Refractory Crohn's Disease — Mayo Clinic Arizona, ScottsdaleA Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) — Barrow Neurological Institute, PhoenixStudy of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis — Xencor Investigative Site, ScottsdaleA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus — AARA Clinical Research, AvondaleA Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease — Research Site 4, Redwood CityA Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants — GSK Investigational Site, ScottsdaleA Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM — Clinical Trial Site, MontclairA Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) — Collaborative Neuroscience Network - CNS, Los AlamitosEvaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events — Diablo Clinical Research, Inc., Walnut CreekA Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease — Irvine Center for Clinical Research /ID# 277752, IrvineA Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment — UAB Pediatric Endocrinology (Part C and Part D), BirminghamA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. — Research Site, AnnistonA First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease — K2 Medical Research, LLC, MaitlandA Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) — Pinnacle Research Group /ID# 278677, AnnistonStudy Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants — Research Site, BirminghamClinical Study of SNK01 in Participants With Moderate Alzheimer's Disease — Behavioral Research Specialists, LLC, GlendaleA Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants — US06-0, La PalmaA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity — MBX Biosciences Investigational Site, DoralA Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) — The Ohio State University (OSU) Wexner Medical Center, ColumbusA Study of LY3971297 in Healthy Participants — CenExel ACT, AnaheimA Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD) — Life Clinical Trials - Colonial Drive - Margate /ID# 276050, MargateR-3750 in Patients With Mild to Moderate Ulcerative Colitis — Amicis Research Center, ValenciaA Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity — Fortrea Clinical Research Unit - Daytona Beach, Daytona BeachEffect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity — Fortrea Clinical Research Unit - Daytona Beach, Daytona BeachStudy of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) — Qps-Mra, Llc., MiamiENA-001 for Opioid Induced Respiratory Depression — South Florida Research Phase I-IV, MiamiDose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis — Mayo Clinic, RochesterA Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD — Clinical Trial Site, La JollaAn Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis — Erick H. Alayo Medical Corporation - Gastro SB Clinic, Chula VistaA Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity. — Research Site, GlendaleA Study of LY4064912 in Healthy Participants and With Overweight or Obesity — Collaborative Neuroscience Network - CNS, Los AlamitosSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoLow Dose IL-2 for the Treatment of Crohn's Disease — Boston Children's Hospital, BostonPilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy — Connecticut Children's Medical Center, HartfordA Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets — Corxel Investigational site, Las VegasA Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity — CenExel ACT- Anaheim Clinical Trials /ID# 283200, AnaheimStudy of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D — Clinical Pharmacology of Miami, MiamiA Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet — Advent Health-Res Inst, OrlandoA Study on How NNC0174-1213 Works in People With Overweight or Obesity. — ICON Early Phase Services, LLC, San AntonioFerritin and Iron Burden in SAH sIRB — Univesity of Iowa Hospital and Clinics, Iowa CityA Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment — University of California - San Diego, La JollaRepurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD — Cedars-Sinai Medical Center, Los AngelesExploration of an Online Education Program to Support Caregivers' Knowledge Transfer — Texas Christian University, Fort WorthDescartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders — H01- Children's National Hospital, Washington D.C.A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) — Climb Bio Investigative Site #100104, AllenA Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity — Parexel International-EPCU Baltimore, BaltimoreMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoAV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980) — Comprehensive Center for Brain Health, Boca RatonInvestigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism — Biomedical Research Imaging Center Marsico Hall (UNC), Chapel HillA Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy — Fortrea Clinical Research Unit, MadisonPhase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders — MD Anderson Cancer Center, HoustonFeasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department — University of Kansas Strawberry Hill Campus, Kansas CityGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression — Wells Medicine, HoustonA Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK — Washington University in St. Louis, St LouisAutologous Stem Cell Transplantation for Crohn's Disease — UPMC Prebyterian- Adult Gastroenterology, PittsburghA Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes — Altasciences Clinical Los Angeles, Inc., CypressA Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight — Altasciences Clinical Kansas, Inc., Overland ParkEvaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women — Pharmaron CPC, Inc, BaltimoreVaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates. — Inova Health System, Falls ChurchA Self-Guided Mobile Intervention for Adults With Binge Eating and Obesity — Drexel University, PhiladelphiaPhysiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents — Childrens Hospital Colorado, AuroraSympathetic Mechanisms in Obesity-Crossover Design — Vanderbilt University Medical Center, NashvilleFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaDiazoxide Suppression Test P&F Study — Columbia University Irving Medical Center, New YorkMetabolic Effects of Angiotensin-(1-7) — Vanderbilt University Medical Center, NashvillePilot Testing a Novel Approach to Pediatric Obesity Treatment — Texas Tech University, LubbockHuman Models of Selective Insulin Resistance: Alpelisib, Part I — Columbia University Irving Medical Center, New YorkGraded Insulin Suppression Test P&F — Columbia University Irving Medical Center, New YorkSemaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants — Celerion Clinical Research, TempeFirst in Human Study in Subjects With Obesity, But Otherwise Healthy — Clinical Pharmacology of Miami, LLC, MiamiA Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants — Medpace Clinical Pharmacology Unit, CincinnatiEffect of Insulin Lowering on Lipogenesis — Columbia University Irving Medical Center, New YorkA Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects — ProSciento, INC, Chula VistaUse of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome — University of Colorado Anschutz Medical Campus, AuroraA Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults — Frontage Clinical Services, Inc., SecaucusA Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity — PAREXEL Glendale/LA EPCU, GlendaleProject SHINE (Sleep Health INitiative for Equity): Culturally Informing a Sleep Extension Intervention for African American Adults — University of Minnesota, MinneapolisA Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity — ICON Early Phase Services, LLC, LenexaPrevention of Progression of Prediabetes, Obesity and CV Risk — University of Texas Health Science Center at San Antonio, San AntonioExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) — Altasciences Clinical LA, Inc., CypressMitigating the Pro-inflammatory Phenotype of Obesity — University of Kansas Medical Center, Kansas CityPhysiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes — Yale Pediatric Diabetes Research, New HavenSafety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity — California Clinical Trials Medical Group, GlendaleThe Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function — Vanderbilt University Medical Center, NashvillePharmacogenetics of Response to GLP1R Agonists — Amish Research Clinic, LancasterEvaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects — Pharmaron CPC, Inc, BaltimoreMechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression — National Institutes of Health Clinical Center, BethesdaAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesPattern Separation in Major Depressive Disorder — New York State Psychiatric Institute (NYSPI), New YorkNeuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder — National Institutes of Health Clinical Center, BethesdaNMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits — Washington University School of Medicine, St LouisModulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains — Lindner Center of Hope, MasonPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityA Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression — Massachusetts General Hospital, Chelsea, ChelseaPET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD) — National Institutes of Health Clinical Center, BethesdaOpen-Label Psilocybin Study in Transdiagnostic Population — Connecticut Mental Health Center - Yale School of Medicine, New HavenPsilocybin in Chronic Low Back Pain and Depression — Johns Hopkins University School of Medicine, BaltimoreStudy of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans — Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West HavenPsilocybin to Treat Depression in Spinal Cord Injury — James J. Peters Department of Veterans Affairs Medical Center, The Bronx[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET — National Institutes of Health Clinical Center, BethesdaAlpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response — Yale University, New HavenEffects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression — Laureate Institute for Brain Research, TulsaDBS for Depression — Zucker Hillside Hospital, QueensACT for Individuals With MNCD and Their Care Partners — Texas Tech University Plaza Building, LubbockPharmacologic Augmentation of TMS for Depression With D-serine — McLean Hospital, BelmontRCT of Psilocybin-assisted CBT for Depression — UCLA Semel Institute, Los AngelesNeural Response to Inflammatory Challenge in Major Depressive Disorder — Laureate Institute for Brain Research, TulsaAdjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression — The University of Texas Health Science Center at Houston, HoustonPET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) — National Institutes of Health Clinical Center, BethesdaUAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy — UAB, BirminghamDeep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD) — UCLA TMS Clinical and Research Service, Los Angeles[18F]F-DOPA Imaging in Patients With Autonomic Failure — Vanderbilt University Medical Center, NashvilleAutologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease — Hoag Memorial Hospital Presbyterian, Newport BeachAssess Fibrin in Brains With AD/ADRD — Massachusetts General Hospital, BostonA Trial to Test Intermittent Deep Brain Stimulation of Nucleus Basalis of Meynert to Treat Alzheimers. — Wellstar MCG Hospital, Neurology Memory Clinic, AugustaNicotinic Acid for the Treatment of Alzheimer's Disease — IU Health Neuroscience Center, IndianapolisDoor-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD) — Onward Health HQ, San LeandroTREAD: Time Restricted Eating Intervention for Alzheimer's Disease — Shiley Marcos Alzheimer's Disease Center, San DiegoSafety and Target Engagement of Centella Asiatica in Cognitive Impairment — Oregon Health & Science University, PortlandLow-Dose Radiotherapy for Alzheimer's Disease — Renaissance Institute of Precision Oncology & Radiosurgery, Winter ParkRifaximin SSD in Dementia Trial — Richmond VA Medical Center, RichmondInterleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease — Houston Methodist Research Institute, HoustonInnate Immunity Stimulation Via TLR9 in Early AD — NYU Langone Health, New YorkExploring the Utility of [18F]3F4AP for Demyelination Imaging — Yale University PET Center, New HavenPET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease — National Institutes of Health Clinical Center, BethesdaSV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy — Yale School of Medicne, Neuro ID Research Program, New HavenPET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases — Brigham MS Center, 60 Fenwood Road, BostonPhase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments — Domino's Farms, Ann ArborFirst-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia — China Basin, UCSF, San FranciscoDouble-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus — National Institutes of Health Clinical Center, BethesdaUC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients — Medical University of South Carolina, CharlestonBAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus — Nationwide Children's, ColumbusEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaEarly Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor — Lucile Packard Children's Hospital, Palo AltoUS Zamto-cel Autoimmune Diseases — Froedtert Hospital and the Medical College of Wisconsin, MilwaukeeCD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus — Children's Hospital of Philadelphia, PhiladelphiaAlnuctamab for Refractory SLE (LATTE Study) — Icahn School of Medicine at Mount Sinai, New YorkREACT-01: Reversing Autoimmunity Through Cell Therapy — Seattle Children's Hospital, SeattleOpen-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. — IRIS Research and Development, LLC, PlantationAn Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab — National Institutes of Health Clinical Center, BethesdaStem Cell Transplantation in Crohn's Disease — Cedars-Sinai Medical Center, Los AngelesStudy to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis — The University of Texas Health Science Center at Houston, HoustonBeta-Hydroxybutyrate Feasibility Treating IBD — University of Texas at Austin, Austin

Showing the 150 nearest — narrow your filters for fewer, closer studies.